The Economics of Reproducibility in Preclinical Research.
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-06-01
|
| Series: | PLoS Biology |
| Online Access: | http://europepmc.org/articles/PMC4461318?pdf=render |